Dyne Therapeutics (DYN) vs Viking Therapeutics (VKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Dyne Therapeutics (DYN) has outperformed Viking Therapeutics (VKTX) over the past year, losing 26.8% versus a loss of 27.7%. Over five years, VKTX leads with a +360.4% price change compared with +5.4% for DYN. Viking Therapeutics is the larger company by market cap ($3.16 billion vs $2.90 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DYN | VKTX |
|---|---|---|
| Share price | $15.50 | $24.77 |
| Market cap | $2.90B | $3.16B |
| 1-day change | -3.31% | -4.14% |
| YTD return | -20.76% | -29.59% |
| 1-year return | -26.82% | -27.70% |
| 5-year return | +5.37% | +360.41% |
| EPS (TTM) | $-3.62 | $-5.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-446.21M | $-359.64M |
| 52-week high | $27.31 | $43.10 |
| 52-week low | $14.00 | $23.82 |
| Distance from 52-week high | -43.23% | -42.53% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +121.48% | +284.82% |
| Average volume | 2.94M | 5.31M |
| Shares outstanding | 187.39M | 127.52M |
| Employees | 322 | 74 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Dyne Therapeutics
DYN stock →Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 322 employees
About Viking Therapeutics
VKTX stock →Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
DYN vs VKTX FAQ
Which is bigger, Dyne Therapeutics or Viking Therapeutics?
Viking Therapeutics (VKTX) is larger, with a market capitalization of $3.16B compared with $2.90B for Dyne Therapeutics (DYN).
Which stock has performed better over the past year, DYN or VKTX?
DYN returned -26.82% over the past 12 months, compared with -27.70% for VKTX (price return, excluding dividends). Past performance does not predict future results.
Are Dyne Therapeutics and Viking Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.